Oncology drugmakers seek the sweet spot between efficacy and tolerability

Cancer drugs were at one time strictly cudgels, hitting a malignancy with the highest dose of chemotherapy a patient could endure. Now, as the industry adds new options like antibody-drug conjugates, targeted therapies and immunotherapies to a market expected to reach more than $484 billion by 2030, experts recognize that oncology treatments should be more targeted.